Search

Displaying results 1791 - 1800 of 6198 in total
  1. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C

  2. Drug

    Enfuvirtide

    go.drugbank.com/drugs/DB00109
    ApprovedInvestigational

    The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.

  3. Drug

    Tazemetostat

    go.drugbank.com/drugs/DB12887
    ApprovedInvestigational

    Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA app...

    Categories: MATE 2-K Inhibitors
  4. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [A237505, A237520] While some patients recover fully following neurological TBE, neurological sequelae can last for years and rare chronic forms of the disease have also been noted. … Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable.

  5. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    _C. botulinum_ is known to produce toxins that can cause botulism in humans. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  6. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.

  7. Target

    Calcium/calmodulin-dependent protein kinase kinase 1

    go.drugbank.com/bio_entities/BE0009418
    TargetHumans

    Calcium/calmodulin-dependent protein kinase that belongs to a proposed calcium-triggered signaling cascade involved in a number of cellular processes. Phosphorylates CAMK1, CAMK1D, CAMK1G and CAMK4. Involved in regulating cell apoptosis....

    Synonyms: CaM-KK 1, CaM-KK alpha
  8. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604]. … It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label].

  9. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.

  10. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo.